Abatacept therapy offers promising results treating juvenile dermatomyositis
- Date:
- March 8, 2023
- Source:
- George Washington University
- Summary:
- Juvenile dermatomyositis, a rare but often severe and chronic systemic autoimmune disease, includes a large number of patients who are treatment resistant, requiring long term immunosuppressive therapy. A small study shows promise using a targeted biologic therapy called abatacept to treat such patients.
- Share:
Juvenile dermatomyositis, a rare but often severe and chronic systemic autoimmune disease, includes a large number of patients who are treatment resistant, requiring long term immunosuppressive therapy. A small open-label study published in Arthritis and Rheumatology shows promise using a targeted biologic therapy called abatacept to treat such patients.
In the 24-week trial, ten patients with juvenile dermatomyositis ages 7 years or older with moderate disease activity who all received abatacept therapy had significant improvements in their muscle strength, physical function, endurance and skin rashes, as well as in the amount of muscle inflammation on MRI. In addition, patients were able to lower the daily dose of corticosteroids during the trial, said Rodolfo V. Curiel, M.D., the study Principal Investigator and an Associate Professor of Medicine at the George Washington University School of Medicine & Health Sciences.
"This study makes an important contribution to the field of juvenile dermatomyositis," Curiel said. "Treatment resistant patients require long-term immunosuppressive therapy with glucocorticoids, methotrexate and other medications. This 24-week clinical trial suggests abatacept may be beneficial and a potentially safe option for refractory juvenile dermatomyositis."
Curiel says the study is the first clinical trial conducted to evaluate the safety and efficacy of abatacept in such patients. Further study must be conducted to verify the findings of this small, pilot study, he says.
"This is a breakthrough for juvenile dermatomyositis. The majority of these treatment-refractory patients improved at least moderately in clinical disease activity measures, as well as in two objective blinded measures, interferon genes and protein markers, reflecting downregulation of a key cytokine signaling pathway in JDM, and muscle inflammation on MRI. These data strengthen the trial findings and promise of abatacept for JDM, although further studies are needed." said Lisa G. Rider, M.D., Head, Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH in Bethesda, Maryland, and Clinical Professor of Medicine at George Washington University School of Medicine & Health Sciences.
The paper, "Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy," was published online in Arthritis and Rheumatology.
The study was supported by Bristol Myers Squibb, Cure Juvenile Myositis Foundation and the GW Medical Faculty Associates. In addition, the National Institute of Environmental Health Sciences and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, which are part of the National Institutes of Health, supported part of the research.
Story Source:
Materials provided by George Washington University. Note: Content may be edited for style and length.
Journal Reference:
- Rodolfo V. Curiel, William Nguyen, Gulnara Mamyrova, Derek Jones, Alison Ehrlich, Kathleen A. Brindle, Shahriar Haji‐Momenian, Robert Sheets, Hanna Kim, Olcay Y. Jones, Lisa G. Rider, Hassan Awal, Adeline Y. Chin, Fatma Dedeoglu, Paul DeMarco, Massimo Gadina, William Hannan, Lawrence Jung, James D. Katz, Susan Kim, Shajia Lu, Aarat Patel, Linda Ray, Kelly Rouster‐Stevens, Gary Simon, Mary Beth Son, Tracy Ting, Wanxia L. Tsai, Peter Weiser. Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy. Arthritis & Rheumatology, 2023; DOI: 10.1002/art.42450
Cite This Page: